Cindy Y. Jiang, MD

Peer-Reviewed Articles

1. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol 8(2):258-262, 2025. e-Pub 2025. PMID: 39709257.
2. Jiang CY, Zhao L, Green MD, Ravishankar S, Towlerton AMH, Scott AJ, Raghavan M, Cusick MF, Warren EH, Ramnath N. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer. Sci Rep 14(1):345, 2024. e-Pub 2024. PMID: 38172168.
3. Jiang CY, Zhao L, Schuetze SM, Chugh R. Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. Oncologist 27(7):595-599, 2022. e-Pub 2022. PMID: 35589095.
4. Jiang CY, Strohbehn GW, Dedinsky RM, Raupp SM, Pannecouk BM, Yentz SE, Ramnath N. Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts. JCO Oncol Pract 17(9):e1362-e1374, 2021. e-Pub 2021. PMID: 34406817.
5. Jiang CY, Niu Z, Green MD, Zhao L, Raupp S, Pannecouk B, Brenner DE, Nagrath S, Ramnath N. It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34321277.
6. Jiang CY, El-Kouri NT, Elliot D, Shields J, Caram MEV, Frankel TL, Ramnath N, Passero VA. Telehealth for Cancer Care in Veterans: Opportunities and Challenges Revealed by COVID. JCO Oncol Pract 17(1):22-29, 2021. e-Pub 2021. PMID: 32970512.
7. Mathur KM, Jiang C, Westerhoff M, Turgeon DK. More Than Just a Flare: Unexpected Findings of Disseminated Histoplasmosis in the Setting of TNF-α Blockade in a Patient with Ulcerative Colitis. Ann Gastroenterol Dig Dis.

Abstracts

1. Jindal T, Zhang L, Jiang C, Kilari D, Alhalabi O, Nizam A, Basu A, Mehmet A, Bilen, Zakharia Y, Milowsky MI, Shah S, Hoimes CJ, Davis NB, Gupta S, Emamekhoo H, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. ASCO 2023.
2. Jiang CY, Jindal T, Epstein IB, Nguyen CB, Nizam A, Bakaloudi DR, Taylor AK, Milowsky MI, Shah S, Hoimes CJ, Bilen MA, Zakharia Y, Emamekhoo H, Grivas P, Gupta S, Bellmunt J, Alva AS, Koshkin VS, Alhalabi O, T Campbell AM. Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. ASCO 2024.
3. Nizam A, Jindal T, Jiang CY, Alhalabi O, Davidsohn MP, Bakaloudi DR, Talukder R, Nguyen CB, Oh E, Taylor AK, Bilen MA, Basu A, Kilari D, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study. GU ASCO 2024.
4. Jiang CY, Hwang H, Jindal T, Qiao W, Epstein I, Nguyen CB, Gupta S, Shah S, Bilen MA, Milowsky MI, Hoimes CJ, Kilari D, Zakharia Y, Emamekhoo H, Grivas P, Bellmunt J, Alva AS, Koshkin VS, Campbell MT, Alhalabi AO. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database. GU ASCO 2024.
5. Jiang CY, Zhang Y, Yu K, Mei Y, Qiao W, Moussa MJ, Chen J, Wang R, Zhao J, Shah AY, Goswami S, Guo CC, Siefker-Radtke AO, Campbell MT, Wang L, Alhalabi O, Gao AJ. Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer. ASCO 2025.
6. Nizam A, Zhang L, Jiang CY, Nguyen CB, Bakaloudi DR, Bilen MA, Barata PM, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Khaki AR, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Alva AS, Campbell MT, Alhalabi O, Koshkin VS. Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. ESMO 2024.
7. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, Asim M, Bilen, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Emamekhoo H, Christopher J, Hoimes, Khaki AR, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. GU ASCO 2024.
8. Jiang C, Ravishankar S, Zhao L, Green M, Towlerton A, Scott A, Raghavan M, Cusick M, Warren EH, Ramnath N. Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer. ASCO 2023.
9. Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn MP, Nguyen CB, Oh E, Taylor AK, Lemke E, Kilari D, Hoimes CJ, Emamekhoo H, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. GU ASCO 2024.
10. Jang A, Jindal T, Jiang CY, Nguyen CB, Nizam A, Alva AS, Grivas P, Bellmunt J, Hoimes CJ, Bilen MA, Emamekhoo H, Milowsky MI, Khaki AR, Gupta S, Campbell MT, Alhalabi O, Chen Z, Fu P, Koshkin VS, Brown JR. Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis. ESMO 2024.
11. Jiang C. The Role of Heavy Metal Resistant Bacteria (Bacillus megaterium, Bacillus licheniformis) on the Bioaccumulation of Lead in Helianthus annuus. Missouri Junior Academy of Science.
12. Jiang C. The Role of Heavy Metal Resistant Bacteria (Bacillus megaterium, Bacillus licheniformis) on the Bioaccumulation of Lead in Helianthus annuus. Intel International Science and Engineering Fair (ISEF).
13. Jiang CY, Madhani N, Shah BK, Dall L. The Sensitivity of Procalcitonin Levels in Patients with Viridans Streptococci Endocarditis. 4th Annual Vijay Babu Raydu Quality and Patient Safety Day.
14. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. UMKC Health Sciences Student Research Summit.
15. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. 5th Annual Vijay Babu Raydu Quality and Patient Safety Day.
16. Jiang CY, Madhani N, Shah BK, Dall L. The Utility of Procalcitonin Levels in the Detection of Viridans Streptococci Endocarditis. Missouri American College of Physicians Scientific Meeting.
17. Jiang CY, Uttal SE, Aggarwal V. A Catastrophic Event [clinical vignette abstract]. American College of Physicians Michigan Chapter Virtual Scientific Meeting.
18. Jiang C, Zhao L, Schuetze S, Chugh R. Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications. University of Michigan Internal Medicine Research Symposium.
19. Jiang C, Zhao L, Schuetze S, Chugh R. Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications. American Society of Clinical Oncology Annual meeting.
20. Jiang CY, Strohbehn GW, Dedinsky RM, Raupp SM, Pannecouk BM, Yentz SE, Ramnath N. Teleoncology for Veterans: High Patient Satisfaction Coupled With Positive Financial and Environmental Impacts. ASCO Quality Care Symposium.
21. Jiang C, Alhalabi O, Haro-Silerio J, Qiao W, Shah AY, Siefker-Radtke AO, Gao J, Goswami S, Alva AS, Koshkin VS, Guo C, Campbell MT. Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV). ASCO 2023.
22. Black S, Yu K, Moussa MJ, Jiang CY, Msaouel P, Meric-Bernstam F, Campbell MT, Wang L, Zhao J, Guo CC, Gao J, Alhalabi O. Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC). ASCO 2025.
23. Jiang C, Jiang C, Alhalabi O, Nguyen CB, Nizam A, Bas A, Zakharia Y, Bilen MA, Brown J, Milowsky M, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva A, Koshkin VS. Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Targeted Anticancer Therapies Congress 2024.
24. Jindal T, Jiang CY, Alhalabi O, Sidhom F, Jang A, Bakaloudi DR, Narula I, Jaime-Casas S, Glover M, Nizam A, Gupta S, Bilen MA, Shah S, Tripathi A, Grivas P, Brown JR, Basu A, Campbell MT, Alva AS, S Koshkin AV. Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study. ASCO GU 2025.
25. Jindal T, Jiang C, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn M, Nizam A, Taylor AK, Nguyen CB, Kilari D, Pywell C, Davis NB, Emamekhoo H, Sonpavde GP, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS. Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study. ASCO 2023.
26. Chu Y, Chen J, Jiang CY, Mei Y, Zhang Y, Siefker-Radtke A, Gao J. FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma. American Association for Cancer Research.